Skip to main content

Table 3 Clinical features of breast cancer patients in TCGA database

From: Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer

Feature

Type

Total

Test

Train

Pvalue

Age

 <  = 65

701 (72.72%)

339 (70.33%)

362 (75.1%)

0.1116

Age

 > 65

263 (27.28%)

143 (29.67%)

120 (24.9%)

 

Gender

FEMALE

964 (100%)

482 (100%)

482 (100%)

1

Stage

Stage I

167 (17.32%)

88 (18.26%)

79 (16.39%)

0.8233

Stage

Stage II

541 (56.12%)

265 (54.98%)

276 (57.26%)

 

Stage

Stage III

215 (22.3%)

107 (22.2%)

108 (22.41%)

 

Stage

Stage IV

18 (1.87%)

8 (1.66%)

10 (2.07%)

 

Stage

unknow

23 (2.39%)

14 (2.9%)

9 (1.87%)

 

T

T1

262 (27.18%)

137 (28.42%)

125 (25.93%)

0.3644

T

T2

545 (56.54%)

271 (56.22%)

274 (56.85%)

 

T

T3

121 (12.55%)

53 (11%)

68 (14.11%)

 

T

T4

33 (3.42%)

19 (3.94%)

14 (2.9%)

 

T

unknow

3 (0.31%)

2 (0.41%)

1 (0.21%)

 

M

M0

799 (82.88%)

395 (81.95%)

404 (83.82%)

0.5436

M

M1

20 (2.07%)

8 (1.66%)

12 (2.49%)

 

M

unknow

145 (15.04%)

79 (16.39%)

66 (13.69%)

 

N

N0

442 (45.85%)

233 (48.34%)

209 (43.36%)

0.2108

N

N1

329 (34.13%)

152 (31.54%)

177 (36.72%)

 

N

N2

106 (11%)

57 (11.83%)

49 (10.17%)

 

N

N3

69 (7.16%)

31 (6.43%)

38 (7.88%)

 

N

unknow

18 (1.87%)

9 (1.87%)

9 (1.87%)

Â